Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Evista is a prescription selective estrogen receptor modulator containing raloxifene hydrochloride. It treats and prevents osteoporosis in postmenopausal women and reduces the risk of invasive breast cancer in postmenopausal women with osteoporosis or a high risk of invasive breast cancer. Each tablet contains 60 mg of raloxifene hydrochloride.
read more about evista ...Raloxifene binds estrogen receptors and acts differently across tissues. It acts as an estrogen agonist in bone, where it decreases bone resorption and turnover and increases bone mineral density. It acts as an estrogen antagonist in breast and uterine tissues.
Evista is used in postmenopausal women for osteoporosis treatment or prevention and for reduction of invasive breast cancer risk under labeled criteria. It is not indicated to treat invasive breast cancer, reduce breast cancer recurrence, or reduce the risk of noninvasive breast cancer.
The recommended dose is one 60 mg tablet once daily with or without food. Calcium and vitamin D supplementation is added when dietary intake is inadequate. Treatment is interrupted at least 72 hours before and during prolonged immobilization due increased venous thromboembolism risk.
Evista carries a boxed warning for increased risk of venous thromboembolism and death from stroke. A current or past history of deep vein thrombosis, pulmonary embolism, or retinal vein thrombosis is a contraindication. Pregnancy is also a contraindication. Stroke risk requires added attention in postmenopausal women with coronary heart disease or elevated coronary risk.
Evista treats and prevents osteoporosis in postmenopausal women and reduces invasive breast cancer risk in selected postmenopausal women.
The recommended dose is 60 mg once daily with or without food.
Yes. The boxed warning concerns venous thromboembolism and death from stroke.
No. Current labeling does not indicate Evista for treatment of invasive breast cancer or reduction of recurrence.
DailyMed - EVISTA (raloxifene hydrochloride) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9. Date Accessed September 30, 2026.
Raloxifene. MedlinePlus. https://medlineplus.gov/druginfo/meds/a698007.html. Date Accessed September 30, 2026.
Raloxifene. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Raloxifene. Date Accessed September 30, 2026.
Raloxifene. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK544233/. Date Accessed September 30, 2026.
Selective Estrogen Receptor Modulators. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548475/. Date Accessed September 30, 2026.